{"entity":{"id":"pkc","kind":"target","name":"Protein kinase C family (PKC)","aka":[],"tldr":"Protein kinase C is a family of signalling enzymes; the AML drug midostaurin started life as a PKC inhibitor and still hits the family alongside FLT3.","summary":"The protein kinase C family (PRKCA and its relatives) transmits signals from calcium and diacylglycerol to growth, survival and secretion pathways. Midostaurin (PKC412) was developed as a PKC inhibitor and gained approval in FLT3-mutant acute myeloid leukaemia and systemic mastocytosis through its FLT3 and KIT activity; PKC remains among its listed targets. PKC-beta inhibitors such as enzastaurin were tested in lymphoma without success.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Protein_kinase_C","links":[{"label":"UniProt P17252: PRKCA","url":"https://www.uniprot.org/uniprotkb/P17252/entry"},{"label":"HGNC:9393 PRKCA","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9393"},{"label":"ChEMBL target CHEMBL2093867","url":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2093867"}],"tags":[],"related":["flt3"],"cancers":["aml"],"sections":[],"technologies":[],"targets":[],"drugs":["midostaurin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"symbol":"PRKCA","biology":"Serine/threonine kinases in conventional, novel and atypical subfamilies; PKC-alpha also drives resistance and vascular permeability signalling.","whereFound":["Ubiquitous","Inhibited by midostaurin in AML and mastocytosis"],"targetClass":"kinase","prevalence":[]},"route":"/targets/pkc/","neighbours":{"target":[{"id":"flt3","kind":"target","name":"FLT3","route":"/targets/flt3/"}],"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"drug":[{"id":"midostaurin","kind":"drug","name":"Midostaurin","route":"/drugs/midostaurin/"}]}}